Trends of Cardiovascular Deaths in Patients With Melanoma From 2005 to 2019: An Analysis Based on SEER Program Database

Document Type

Conference Proceeding

Publication Date

11-7-2023

Publication Title

Circulation

Abstract

Introduction: Melanoma is the fifth most common cancer diagnosis in the United States. With recent advances in treatment modalities, including immune checkpoint inhibitors (ICIs), targeted therapies, there has been improvement in survival among melanoma patients. However, increasing resistance and treatment related adverse effects (TrAEs) are being reported including cardiovascular side effects.

Objectives: To evaluate the trend of cardiovascular specific death rate among patients with melanoma.

Methods: We used Surveillance, Epidemiology, and End Results (SEER) Program database 17 registries from 2000 to 2019 and SEER*Stat Version 8.4.1 software to analyze the data using the rate session. Joinpoint software, version 4.7.1.0 was used to create log-linear time trends annually.

Results: Our study included 301,632 patients with melanoma from 2005 to 2019. The annual percentage change (APC) of melanoma was 0.46% (95% CI -1.45 to 1.07, p>0.05) annually from 2005 to 2011 and 3.33% (95% CI 1.79 to 4.27, p<0.05) annually from 2011 to 2014 and the incidence rate decreased by 0.06% (95% CI -1.44 to 0.5, p>0.05) annually from 2014 to 2019. Melanoma specific mortality rate increased annually by 2.03 % (95% CI 0.78 to 3.94, P <0.05) from 2005 to 2013 and decreased by 5.49% annually (95% CI -8.65 to -3.65, P <0.05) from 2013 to 2019. Cardiovascular disease specific mortality rate increased by 7.08% annually (95% CI 4.66 to 9.64, P <0.05) from 2005 to 2019. (Figure 1)

Conclusion: Our study shows that there has been an annual increase in cardiovascular specific mortality rate from 2005 to 2019, while there was annual decrease in melanoma specific mortality rate from 2013 to 2019. Increase in cardiovascular specific death rates could be due to the direct toxicity of newer therapies and prolonged survival, which further could be due to advancement in diagnostics and newer therapies.

Volume

148

Issue

Suppl 1

First Page

A16756

Comments

American Heart Association Scientific Sessions, November 11-13, 2023, Philadelphia, PA

DOI

10.1161/circ.148.suppl_1.16756

Link to Full Text

Share

COinS